A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Becker muscular dystrophy (BMD) is a type of muscular dystrophy ... Dystrophinopathies (including BMD and DMD) happen due to certain mutations in the genetic code. One gene, for instance, controls ...

The determination comes after recruitment and dosing in certain trials were paused after a young patient died due to acute ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

Global Duchenne Muscular Dystrophy Drugs Market value attained USD 3.9 Billion in 2025. The market will achieve USD 6.5 ...

adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the ...

adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the ...